XAIR - Beyond Air jumps on FDA nod for LungFit system to treat respiratory failure in infants

Beyond Air (NASDAQ:XAIR) stock gained after hours on Tuesday after the company said the U.S. FDA had approved its nitric oxide generator and delivery system LungFit PH to treat infants with hypoxic respiratory failure. XAIR stock added ~25% to $7.25. XAIR said this was the first FDA-approved product for the company. XAIR said the LungFit PH system eliminates the need for traditional nitric oxide tanks from the hospital setting. The company is planning a broader U.S. hospital launch in H1 2023.

For further details see:

Beyond Air jumps on FDA nod for LungFit system to treat respiratory failure in infants